Fig. 2: lincNMR is induced in multiple cancer types and affects tumor growth in vivo.

a LincNMR is expressed and regulated in multiple cancer types (N = normal, T = tumor; data obtained from TCGA data portal). LIHC = hepatocellular carcinoma (N = 50, T = 200), BRCA = breast cancer (N = 105, T = 105), LUAD = lung adenocarcinoma (N = 58, T = 488), LUSC = lung squamous cell carcinoma (N = 17, T = 220), BLCA = bladder cancer (N = 30, T = 252), CESC = cervical serous carcinoma (N = 3, T = 196). Data are represented as log2 RPKM. b Timecourse of BrdU incorporation assays in HLE cells showing induction and maintenance of proliferation inhibition up to 168 h post lincNMR knockdown with 10 nM siPOOLs (n = 3). Data are normalized to negative control siPOOL. Data represent mean, and error bars represent SEM. c Chick chorioallantoic membrane (CAM) assay: picture showing CAM-harvested tumors formed from HLE cells transfected with lincNMR or control siPOOLs. Tumors were harvested on day 6. LincNMR-depleted cells gave rise to smaller tumors (the number of chick embryos used in total: si-negative control = 24, si-lincNMR-A = 27, si-lincNMR-B = 29). d Quantification of tumors harvested from CAM assay: decreased tumor weight in lincNMR-depleted tumors compared to the control group. a, b, d Significance was calculated by unpaired, two-tailed t test with *P < 0.05; **P < 0.01; ***P < 0.001.